Patents by Inventor Susanne Sebens

Susanne Sebens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 9260521
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 16, 2016
    Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTS
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY
    Publication number: 20140120117
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 1, 2014
    Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • Treatment of tumors using specific anti-L1 antibody
    Patent number: 8580258
    Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 12, 2013
    Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AG
    Inventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
  • TREATMENT OF CHEMOTHERAPY- OR RADIOTHERAPY-RESISTANT TUMORS
    Publication number: 20080299123
    Abstract: The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy.
    Type: Application
    Filed: October 5, 2007
    Publication date: December 4, 2008
    Inventors: Peter Altevogt, Alexander Stoeck, Daniela Gast, Susanne Sebens Muerkoster, Heiner Schafer